RE: New VAL CEO30 Jul 2024 13:49
New VAL CEO spun out an asset from VAL and went on to $250mln
Hopefully he...after 3yrs. .can finally get VAL201 over the line (he certainly seemed confident In his LinkedIn post on day of his appointment this week)
Potential for PYC
Physiomics will receive a fee (capped at £6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection.